Chondromalacia: Etiology, Management Challenges, and Alternative Treatment

10.4247/AM.2024.ACE279

Po-Ling Yu；Wei-Jie Wang；Wen-Long Cho

exosome ； chondromalacia ； patellae ； TELOXOME

Adaptive Medicine

16卷（2024 / 05 / 15）

10 - 12

英文

In this study, a patient received two local injections of TELOXOME, a novel stem cell-derived agent developed by ContiNew Medical. The injections were administered to the patient's left knee, with the injections separated by 3 weeks. The patient underwent magnetic resonance imaging (MRI) of the knee before and at 6 months after the TELOXOME injections. The MRI scans revealed a significant improvement in chondromalacia following the two TELOXOME injections. This finding indicates that TELOXOME may be an effective treatment option for chondromalacia, especially in cases where traditional treatments have failed.